I know they've streamlined their clinical trial and approval processes. I believe so that a product can be marketed after (during?) phase II.
And every stem cell/regenerative medicine biotech is hyping Japan as the nirvana of capital, innovation and springboard to "$ multi-billion breakthrough".
That said, some companies have obtained significant $$$ there, and are certainly trying to take advantage of the streamlined approval processes to get their products to market.
Will be interesting to see how much of the hype bears fruit.
I know they've streamlined their clinical trial and approval...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.010(1.01%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.01 | 94.3¢ | $8.618M | 8.821M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43508 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 40703 | 5 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |